Interest Paid, Excluding Capitalized Interest, Operating Activity
Alnylam Pharmaceuticals Interest Paid, Excluding Capitalized Interest, Operating Activity decreased by 43.3% to $64.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.9%, from $68.93M to $64.20M. Over 4 years (FY 2021 to FY 2025), Interest Paid, Excluding Capitalized Interest, Operating Activity shows an upward trend with a 72.6% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
Lower cash interest payments improve free cash flow and liquidity, whereas higher payments indicate increased debt service pressure.
Detailed definition
The actual cash outflow for interest payments during the period, net of any interest income or capitalized interest adju...
Peer comparison
Standard cash flow statement line item; highly comparable across all public companies.
other_interest_paid_netHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.16M | $6.16M | $6.16M | $14.12M | $14.94M | $14.87M | $1.30M | $13.91M | $3.22M | $9.55M | $5.44M | $30.95M | $8.16M | $16.15M | $12.33M | $68.93M | $12.57M | $23.89M | $113.32M | $64.20M |
| QoQ Change | — | +0.0% | +0.0% | +129.1% | +5.8% | -0.5% | -91.2% | +967.7% | -76.9% | +196.9% | -43.0% | +468.5% | -73.6% | +98.0% | -23.6% | +459.1% | -81.8% | +90.1% | +374.3% | -43.3% |
| YoY Change | — | — | — | — | +142.4% | +141.3% | -78.9% | -1.5% | -78.5% | -35.8% | +317.7% | +122.4% | +153.6% | +69.1% | +126.5% | +122.8% | +54.1% | +48.0% | +819.0% | -6.9% |
Interest Paid, Excluding Capitalized Interest, Operating Activity at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's interest paid, excluding capitalized interest, operating activity?
- Alnylam Pharmaceuticals (ALNY) reported interest paid, excluding capitalized interest, operating activity of $64.20M in Q1 2026.
- How has Alnylam Pharmaceuticals's interest paid, excluding capitalized interest, operating activity changed year-over-year?
- Alnylam Pharmaceuticals's interest paid, excluding capitalized interest, operating activity decreased by 6.9% year-over-year, from $68.93M to $64.20M.
- What is the long-term trend for Alnylam Pharmaceuticals's interest paid, excluding capitalized interest, operating activity?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's interest paid, excluding capitalized interest, operating activity has grown at a 72.6% compound annual growth rate (CAGR), from $24.66M to $218.71M.
- What does interest paid, excluding capitalized interest, operating activity mean?
- The net cash paid for interest during the period.